ARCH Venture Partners

US biotech VC

Explore the full dataset

2018 YTD investments

Company name Date Series Deal amount ($M) Therapeutic area Stage Role
Gossamer Bio 01/05/2018 Series A $100

Gastrointestinal disease

Inflammation

Oncology

Immunology

Pulmonology

Phase 2 Lead investor
insitro 05/02/2018 Series A $100

Undisclosed

Preclinical Lead investor
Beam Therapeutics 05/14/2018 Series A $87

Undisclosed

Preclinical Lead investor
Brii Bio 05/24/2018 Series A $260

Undisclosed

Undisclosed Lead investor
Cstone Pharmaceuticals 05/10/2018 Series B $260

Oncology

Phase 1/2 New non-lead investor
Scholar Rock 01/03/2018 Series C $47

Oncology

Rare disease

Preclinical Existing investor
Unity Biotechnology 03/19/2018 Series C $55

Aging

Phase 1 Existing investor
Hua Medicine 03/27/2018 Series D + E $117

Diabetes

Phase 3 Existing investor
Nohla Therapeutics 05/16/2018 Series B $45

Hematology

Oncology

Phase 2 Existing investor
Metacrine 06/06/2018 Series C $65

Gastrointestinal disease

Liver disease

Metabolic disorders

Phase 1 Existing investor
Hangzhou Just Biotherapeutics 06/06/2018 Series B $35

Metabolic disorders

Oncology

Rare disease

Preclinical Existing investor
Gossamer Bio 07/23/2018 Series B $230

Gastrointestinal disease

Inflammation

Oncology

Immunology

Pulmonology

Phase 2 Existing investor
Omniome 07/30/2018 Series B $60 Existing investor
Karuna Pharmaceuticals 08/02/2018 Series A $42

Alzheimer's disease

Neurology

Pain

Phase 2 Lead investor
Magnolia Neurosciences 08/13/2018 Series A $31

Alzheimer's disease

Neurodegenerative

Preclinical New non-lead investor
OncoResponse 09/11/2018 Series B $40

Oncology

Preclinical Existing investor
KSQ Therapeutics 09/28/2018 Series C $80

Autoimmune

Oncology

Rare disease

Preclinical Existing investor
Glympse Bio 10/09/2018 Series A $22

Liver disease

Preclinical Lead investor
Juno Therapeutics 04/24/2014 Series A $176 Phase 2 Lead investor
Juno Therapeutics 08/05/2014 Series B $134 Phase 2 Existing investor
HiberCell 02/07/2019 Series A $61

Oncology

Preclinical Lead investor
Maze Therapeutics 02/28/2019 Series A $191

Rare disease

Undisclosed

Discovery Lead investor
Beam Therapeutics 03/06/2019 Series B $135

Undisclosed

Preclinical Existing investor
Karuna Pharmaceuticals 03/18/2019 Series B $80

Alzheimer's disease

Neurology

Pain

Phase 2 Lead investor
Vividion Therapeutics 04/30/2019 Series B $82

Oncology

Immunology

Preclinical Existing investor
Verve Therapeutics 05/07/2019 Series A $58

Cardiovascular disease

Preclinical New non-lead investor
Locana 05/22/2019 Series A $55

Rare disease

Preclinical Lead investor
BlackThorn Therapeutics 06/13/2019 Series B $76

Neurology

Phase 1 Existing investor
Encoded Therapeutics 06/26/2019 Series C $104

Epilepsy

Neurology

Rare disease

Preclinical Existing investor
Boundless Bio 09/19/2019 Series A $46

Oncology

Discovery Lead investor
Lyell Immunopharma 02/08/2019 Series B $179

Oncology

Immunology

Preclinical Existing investor
eGenesis 11/07/2019 Series B $100

Cardiovascular disease

Liver disease

Metabolic disorders

Renal disease

Pulmonology

Preclinical Existing investor
Aspen Neuroscience 12/12/2019 Seed $6

Neurodegenerative

Preclinical New non-lead investor
Epirium Bio 12/18/2019 Series A $85

Aging

Rare disease

Preclinical Lead investor
EQRx 01/12/2020 Series A $200

Undisclosed

Undisclosed Lead investor
Sonoma Biotherapeutics 02/06/2020 Series A $40

Autoimmune

Discovery New non-lead investor
Volastra Therapeutics 02/11/2020 Seed $12

Oncology

Discovery New non-lead investor
Aspen Neuroscience 04/01/2020 Series A $70

Neurodegenerative

Preclinical Existing investor
ROME Therapeutics 04/27/2020 Series A $50

Autoimmune

Oncology

Discovery Lead investor
Erasca 04/27/2020 Series B $200

Oncology

Discovery Lead investor
insitro 05/26/2020 Series B $143

Undisclosed

Preclinical Existing investor
Autobahn Therapeutics 06/09/2020 Series B $76

Neurology

Rare disease

Preclinical Lead investor
Verve Therapeutics 06/11/2020 Series A $63

Cardiovascular disease

Preclinical Existing investor
JW Therapeutics 06/09/2020 Series B $100

Oncology

Phase 1 Existing investor
BitBio 06/13/2020 Series A $42

Cardiovascular disease

Neurodegenerative

Neurology

Oncology

Discovery New non-lead investor
Sana Biotechnology 06/23/2020 Series A $700

Cardiovascular disease

Diabetes

Metabolic disorders

Immunology

Preclinical Lead investor
Glympse Bio 07/15/2020 Series B $47

Liver disease

Preclinical Existing investor
Encoded Therapeutics 07/22/2020 Series D $135

Epilepsy

Neurology

Rare disease

Preclinical Existing investor
Nutcracker Therapeutics 09/23/2020 Series B $60

Oncology

Preclinical Lead investor
Dewpoint Therapeutics 09/29/2020 Series B $77

Cardiovascular disease

Neurodegenerative

Oncology

Discovery Lead investor
Sonoma Biotherapeutics 09/30/2020 Series A $30

Autoimmune

Discovery Lead investor
Walden Biosciences 10/06/2020 Series A $51

Renal disease

Preclinical Lead investor
National Resilience 11/23/2020 Series B $750

Undisclosed

Undisclosed Lead investor
SciNeuro Pharmaceuticals 12/08/2020 Series A $100

Neurodegenerative

Neurology

Rare disease

Undisclosed Lead investor
Remix Therapeutics 12/08/2020 Series A $81

Autoimmune

Neurology

Oncology

Rare disease

Discovery New non-lead investor
LifeMine Therapeutics 01/07/2021 Series B $50

Oncology

Immunology

Preclinical Existing investor
ImmuneID 02/17/2021 Seed $17

Autoimmune

Infectious disease

Inflammation

Oncology

Immunology

Preclinical New non-lead investor
Vividion Therapeutics 02/24/2021 Series C $135

Oncology

Immunology

Preclinical Existing investor
insitro 03/15/2021 Series C $400

Undisclosed

Preclinical Existing investor
Volastra Therapeutics 04/06/2021 Seed $32

Oncology

Discovery Existing investor
Jaguar Gene Therapy 04/13/2021 Series B $139

Autoimmune

Neurology

Rare disease

Preclinical New non-lead investor
Treeline Biosciences 04/26/2021 Series A $212

Oncology

Preclinical Lead investor
Interline Therapeutics 05/13/2021 Series A $92

Inflammation

Oncology

Preclinical Lead investor
HiberCell 05/19/2021 Series B $67

Oncology

Preclinical Existing investor
Omniome 01/09/2020 Series C $60 Existing investor
OncoResponse 03/31/2021 Series C $41

Oncology

Preclinical Existing investor
ImmuneID 06/26/2021 Series A $50

Autoimmune

Infectious disease

Inflammation

Oncology

Immunology

Preclinical Existing investor
Prime Medicine 07/13/2021 Series B $200

Hematology

Liver disease

Neurology

Ophthalmology

Rare disease

Pulmonology

Preclinical Lead investor
Slingshot Biosciences 07/22/2021 Series A $23

Undisclosed

Undisclosed New non-lead investor
Sonoma Biotherapeutics 08/04/2021 Series B $265

Autoimmune

Discovery Existing investor
ROME Therapeutics 09/14/2021 Series B $77

Autoimmune

Oncology

Discovery Existing investor
Neumora Therapeutics 10/07/2021 Series A $500

Neurodegenerative

Neurology

Phase 2 Lead investor
Mozart Therapeutics 10/26/2021 Series A $55

Autoimmune

Gastrointestinal disease

Inflammation

Preclinical Lead investor
Arbor Biotechnologies 11/09/2021 Series B $215

Liver disease

Neurology

Preclinical Existing investor
Generate Biomedicines 11/18/2021 Series B $370

Undisclosed

Preclinical New non-lead investor
ONI 01/20/2022 Series B $75

Undisclosed

Undisclosed Lead investor
Dewpoint Therapeutics 02/03/2022 Series C $150

Cardiovascular disease

Neurodegenerative

Oncology

Discovery Existing investor
hC Bioscience 02/23/2022 Series A $24

Rare disease

Preclinical Lead investor
Nutcracker Therapeutics 03/14/2022 Series C $167

Oncology

Preclinical Lead investor
LifeMine Therapeutics 03/23/2022 Series C $175

Oncology

Immunology

Preclinical Existing investor
Be Biopharma 04/14/2022 Series B $130

Autoimmune

Infectious disease

Oncology

Rare disease

Preclinical Lead investor
Pheast Therapeutics 04/26/2022 Series A $76

Oncology

Immunology

Preclinical Lead investor
Aspen Neuroscience 05/09/2022 Series B $148

Neurodegenerative

Preclinical Existing investor
Remix Therapeutics 05/17/2022 Series B $70

Autoimmune

Neurology

Oncology

Rare disease

Discovery Existing investor
National Resilience 06/06/2022 Series D $625

Undisclosed

Undisclosed Existing investor
National Resilience 08/01/2021 Series C $600

Undisclosed

Undisclosed investor
Sironax 08/02/2022 Series B $200

Aging

Phase 1/2 Existing investor
Vilya 08/29/2022 Series A $50

Undisclosed

Preclinical Lead investor
Pretzel Therapeutics 09/12/2022 Series A $72

Aging

Metabolic disorders

Oncology

Rare disease

Preclinical Lead investor
Neumora Therapeutics 10/11/2022 Series B $112

Neurodegenerative

Neurology

Phase 2 Existing investor
Treeline Biosciences 10/17/2022 Series A $261

Oncology

Preclinical New non-lead investor
HI-Bio 11/01/2022 Series A $120

Autoimmune

Inflammation

Immunology

Phase 1 Lead investor
hC Bioscience 11/04/2022 Series A $16

Rare disease

Preclinical Existing investor
Carrick Therapeutics 12/01/2022 Series C $60

Oncology

Phase 2 Existing investor
SonoThera 12/05/2022 Series A $61

Undisclosed

Preclinical Lead investor
Akamis Bio 01/05/2023 Late stage $30

Oncology

Immunology

Phase 1 Lead investor
Aera Therapeutics 02/16/2023 Series B $193

Undisclosed

Preclinical Lead investor
Chroma Medicine 03/01/2023 Series B $135

Rare disease

Preclinical New non-lead investor
Rapport Therapeutics 03/07/2023 Series A $100

Neurology

Phase 1 New non-lead investor
Volastra Therapeutics 03/07/2023 Series A $60

Oncology

Discovery Lead investor
Orbital Therapeutics 04/26/2023 Series A $270

Antiviral

Infectious disease

Immunology

Preclinical Lead investor
Boundless Bio 05/16/2023 Series C $100

Oncology

Discovery Existing investor
Myeloid Therapeutics 05/18/2023 Series B $73

Oncology

Immunology

Preclinical New non-lead investor
Bitterroot Bio 06/07/2023 Series A $145

Cardiovascular disease

Inflammation

Immunology

Preclinical Lead investor
Mozart Therapeutics 06/07/2023 Series A $25

Autoimmune

Gastrointestinal disease

Inflammation

Preclinical Existing investor
Rapport Therapeutics 08/23/2023 Series B $150

Neurology

Phase 1 Existing investor
ROME Therapeutics 09/12/2023 Series B $72

Autoimmune

Oncology

Discovery Existing investor
Generate Biomedicines 09/14/2023 Series C $273

Undisclosed

Preclinical Existing investor
Magnet Biomedicine 09/19/2023 Series A $50

Cardiovascular disease

Oncology

Immunology

Preclinical Lead investor
Gate Bioscience 11/01/2023 Series A $60

Undisclosed

Preclinical New non-lead investor
Tome Biosciences 12/12/2023 Series B $213

Autoimmune

Liver disease

Rare disease

Preclinical New non-lead investor

2018 YTD exits: this feature is in beta, data may be incomplete


IPOs

Company Date Amount ($M) Post-money ($M) Therapeutic area
Singular Genomic Systems 05/26/2021 $224.4 $1684.4

Gastrointestinal disease

Inflammation

Oncology

Immunology

Pulmonology

Erasca 07/15/2021 $300.0 $2068.1

Undisclosed

Verve Therapeutics 06/16/2021 $266.7 $953.6

Undisclosed

Lyell Immunopharma 06/16/2021 $425.0 $4665.9

Undisclosed

Prime Medicine 10/19/2022 $175.0 $1675.8

Oncology

Neumora Therapeutics 09/14/2023 $250.1 $2759.6

Oncology

Rare disease